Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its ...

Caption: Structure of a HIV capsid (Left) Central slice view of a HIV virus-like particle with pore-forming toxin on the membrane (Middle) Atomic model of a HIV capsid (Right) Density map of HIV ...

The HIV-1 capsid (pink) cracks the rings of the nuclear pore complex (orange, green and blue rings) as it traverses the channel. Credit: Philipp Kreysing Using state-of-the-art cellular tomography ...

An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...

An international team of researchers led by UNSW Sydney medical researchers now have the details on how this novel drug pushes the HIV capsid to breaking point, stopping the virus in its tracks ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Caption The genetic material of the HIV virus is encased in multiple structures that hide it from the host immune system. The capsid, in blue, protects the virus after it enters a cell and ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

Sunlenca – based on HIV capsid inhibitor lenacapavir – is intended as an add-on to current treatment for the infection. In trials, 81% of participants taking the regimen achieved HIV RNA ...

More information: Jan Philipp Kreysing et al, Passage of the HIV capsid cracks the nuclear pore, Cell (2025). DOI: 10.1016/j.cell.2024.12.008 Provided by Max Planck Society ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.